This page shows the latest IL-13 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Almirall has revealed topline results from its one-year analysis of the efficacy and safety of its investigational IL-13 inhibitor, lebrikizumab, to treat patients with moderate-to-severe atopic dermatitis ... Lebrikizumab is a novel, monoclonal antibody
The pharma giant is also set to gain an additional phase 3 candidate from the deal – lebrikizumab, a monoclonal antibody designed to bind to IL-13 that is being evaluated for ... Dermira gained the bulk of the rights to the IL-13 inhibitor in a
Atopic dermatitis was poorly-served with therapies for years, but latterly has seen new treatment options come to market including Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent ... There are a number of drugs coming through the collective
Dupixent – an IL-4 and IL-13 inhibitor that is one of the fast-growing drugs in both Sanofi and Regeneron’s portfolios – is already approved in the US for atopic
The drug earned £152m ($193m) in Q1 this year (up 41% on the same period a year earlier) but is also facing competition from other IL-5 inhibitors including AstraZeneca’s ... Another significant challenger in the market is Sanofi's Dupixent, a dual
The dual IL-4 and IL-13 inhibitor has just gained approval for the new use in the European Union, and the partners are amassing data which shows it can alleviate
More from news
Approximately 1 fully matching, plus 23 partially matching documents found.
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...